Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Terminated Phase 4 Interventional Results available

Study to Evaluate the Efficacy and Safety of the Combination of Valturna and Amlodipine or Valturna and Chlorthalidone Versus Valturna Alone in Patients With Stage 2 Hypertension and Diabetes

ClinicalTrials.gov ID: NCT01368536

Public ClinicalTrials.gov record NCT01368536. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 12:01 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A 12-week, Multi-Center, Randomized Double-Blind, Active Control Parallel Group Study to Evaluate the Efficacy and Safety of the Combination of Valturna and Amlodipine or Valturna and Chlorthalidone Versus Valturna Alone in Patients With Stage 2 Hypertension and Diabetes

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This was a study to assess the safety and efficacy of Valturna and amlodipine or Valturna and chlorthalidone when compared to Valturna alone in patients with stage 2 hypertension and diabetes mellitus 2.

Study identification

NCT ID
NCT01368536
Recruitment status
Terminated
Study type
Interventional
Phase
Phase 4
Lead sponsor
Novartis Pharmaceuticals
Industry
Enrollment
975 participants

Conditions and interventions

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
May 2011 (Type not available)
Primary completion
Feb 2012 (Actual)
Completion
Feb 2012 (Actual)
Last update posted
Mar 21, 2013

2011 – 2012

United States locations

U.S. sites
95
U.S. states
30
U.S. cities
81
Facility City State ZIP Site status
Novartis Investigative Site Athens Alabama 35611 —
Novartis Investigative Site Florence Alabama 35630 —
Novartis Investigative Site Huntsville Alabama 35801 —
Novartis Investigative Site Montgomery Alabama 36106 —
Novartis Investigative Site Muscle Shoals Alabama 35662 —
Novartis Investigative Site Chandler Arizona 85224 —
Novartis Investigative Site Little Rock Arkansas 72204 —
Novartis Investigative Site Buena Park California 90620 —
Novartis Investigative Site Fair Oaks California 95628 —
Novartis Investigative Site Fresno California 93726 —
Novartis Investigative Site Healdsburg California 95448 —
Novartis Investigative Site Los Angeles California 90057 —
Novartis Investigative Site Orangevale California 95662 —
Novartis Investigative Site Riverside California 92506 —
Novartis Investigative Site Roseville California 95661 —
Novartis Investigative Site Sacramento California 95816 —
Novartis Investigative Site Santa Ana California 92701 —
Novartis Investigative Site West Covina California 91790 —
Novartis Investigative Site Shelton Connecticut 06484 —
Novartis Investigative Site Fort Lauderdale Florida 33306 —
Novartis Investigative Site Fort Lauderdale Florida 33308 —
Novartis Investigative Site Jupiter Florida 33458 —
Novartis Investigative Site Lauderdale Lakes Florida 33319 —
Novartis Investigative Site North Miami Beach Florida 33169 —
Novartis Investigative Site St. Petersburg Florida 33701 —
Novartis Investigative Site Tampa Florida 33603 —
Novartis Investigative Site West Palm Beach Florida 33409 —
Novartis Investigative Site Augusta Georgia 30904 —
Novartis Investigative Site Honolulu Hawaii 96813 —
Novartis Investigative Site Chicago Illinois 60607 —
Novartis Investigative Site Chicago Illinois 60610 —
Novartis Investigative Site Chicago Illinois 60617 —
Novartis Investigative Site Gurnee Illinois 60031 —
Novartis Investigative Site Lansing Kansas 66043 —
Novartis Investigative Site Topeka Kansas 66606 —
Novartis Investigative Site Beltsville Maine 20705 —
Novartis Investigative Site Waltham Massachusetts 02453 —
Novartis Investigative Site Wellesley Hills Massachusetts 02481-2106 —
Novartis Investigative Site Brooklyn Center Minnesota 55430-2168 —
Novartis Investigative Site Belzoni Mississippi 39038 —
Novartis Investigative Site Jackson Mississippi 39209 —
Novartis Investigative Site Picayune Mississippi 39466 —
Novartis Investigative Site Kansas City Missouri 64111 —
Novartis Investigative Site Ozark Missouri 65721 —
Novartis Investigative Site St Louis Missouri 63110-1093 —
Novartis Investigative Site St Louis Missouri 63128 —
Novartis Investigative Site St Louis Missouri 63141 —
Novartis Investigative Site Omaha Nebraska 68134 —
Novartis Investigative Site Henderson Nevada 89014 —
Novartis Investigative Site Las Vegas Nevada 89119 —
Novartis Investigative Site Toms River New Jersey 08753 —
Novartis Investigative Site Toms River New Jersey 08755 —
Novartis Investigative Site Trenton New Jersey 08629 —
Novartis Investigative Site Buffalo New York 14209 —
Novartis Investigative Site Camillus New York 13031 —
Novartis Investigative Site Asheboro North Carolina 27204 —
Novartis Investigative Site Asheville North Carolina 28801 —
Novartis Investigative Site Greensboro North Carolina 27401 —
Novartis Investigative Site Greensboro North Carolina 27408 —
Novartis Investigative Site Shelby North Carolina 28150 —
Novartis Investigative Site Winston-Salem North Carolina 27103 —
Novartis Investigative Site Fargo North Dakota 58103 —
Novartis Investigative Site Cincinnati Ohio 45219 —
Novartis Investigative Site Cincinnati Ohio 45224 —
Novartis Investigative Site Columbus Ohio 43201 —
Novartis Investigative Site Lyndhurst Ohio 44124 —
Novartis Investigative Site Zanesville Ohio 43701 —
Novartis Investigative Site Oklahoma City Oklahoma 73132-4904 —
Novartis Investigative Site Oklahoma City Oklahoma 73134 —
Novartis Investigative Site Portland Oregon 97232 —
Novartis Investigative Site Reading Pennsylvania 19609 —
Novartis Investigative Site Uniontown Pennsylvania 15401 —
Novartis Investigative Site Wallingford Pennsylvania 19086 —
Novartis Investigative Site Charleston South Carolina 29407 —
Novartis Investigative Site Charleston South Carolina 29412 —
Novartis Investigative Site Easley South Carolina 29640 —
Novartis Investigative Site Greenville South Carolina 29615 —
Novartis Investigative Site Mt. Pleasant South Carolina 29464 —
Novartis Investigative Site Summerville South Carolina 29485 —
Novartis Investigative Site Varnville South Carolina 29944 —
Novartis Investigative Site Fayetteville Tennessee 33734 —
Novartis Investigative Site Arlington Texas 76012 —
Novartis Investigative Site Austin Texas 78728-6904 —
Novartis Investigative Site Austin Texas 78735 —
Novartis Investigative Site Dallas Texas 75235 —
Novartis Investigative Site Houston Texas 77025 —
Novartis Investigative Site Houston Texas 77074 —
Novartis Investigative Site Houston Texas 77081 —
Novartis Investigative Site Houston Texas 77083 —
Novartis Investigative Site Lake Jackson Texas 77566 —
Novartis Investigative Site Pasadena Texas 77504 —
Novartis Investigative Site Plano Texas 75093 —
Novartis Investigative Site Richardson Texas 75080 —
Novartis Investigative Site St. George Utah 84790 —
Novartis Investigative Site Arlington Virginia 22203 —

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 2 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT01368536, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Mar 21, 2013 · Synced Oct 22, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT01368536 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →